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The db/db mouse develops features of type II diabetes
mellitus as the result of impaired signaling through its
abnormal leptin receptor. In spite of accurate metabolic
features of diabetes, renal disease manifestations in these
mice are not as severe as in humans suggesting the presence
of protective genes. There is a growing body of evidence in
humans for the relevance of vitamin D in diabetes. Here we
followed a large cohort of db/db mice and their non-diabetic
db/þ littermates. Transcriptional profiling revealed
significant upregulation of 23 genes involved in Ca2þ
homeostasis and vitamin D metabolism in db/db glomeruli
relative to db/þ glomeruli. Increased glomerular expression
of vitamin D3 1a-hydroxylase, vitamin D binding protein,
calbindins D9K and D28K, and calcyclin mRNA was confirmed
by quantitative reverse transcription–polymerase chain
reaction in 20-, 36-, and 52-week-old db/db glomeruli.
Although vitamin D3 1a-hydroxylase protein was primarily
expressed and upregulated in db/db renal tubules, it was also
expressed in glomerular podocytes in vivo. Serum
1,25-dihydroxyvitamin D3 and urinary Ca
2þ excretion were
increased 43-fold in db/db mice compared to db/þ mice.
Cultured glomerular podocytes had mRNA for vitamin D3
1a-hydroxylase, vitamin D receptor, and calbindin D28K, each
of which was increased in high glucose conditions. High
glucose also led to enhanced production of fibronectin
and collagen IV protein, which was blocked by 1,25-
dihydroxyvitamin D3. These results show that vitamin D
metabolism is altered in db/db mice leading to metabolic and
transcriptional effects. The podocyte is affected by paracrine
and potentially autocrine effects of vitamin D, which may
explain why db/db mice are resistant to progressive diabetic
nephropathy.
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Diabetes mellitus is characterized by relative or absolute
insulinopenia and hyperglycemia. Type I diabetes mellitus is
due to autoimmune pancreatic b-cell destruction, whereas
type II diabetes mellitus is more complex, and includes
abnormalities of b-cell function and tissue resistance to
insulin effects.1,2 Although clearly a major hormonal
regulator of Ca2þ , vitamin D has non-calcemic effects on
the immune system and in b-cells to facilitate insulin
production.3–7 Related to this is the growing clinical and
epidemiological evidence for a protective role of vitamin D in
diabetes mellitus, and conversely, the increased risk with its
deficiency.8,9
Diabetic nephropathy occurs in up to half of patients with
diabetes mellitus and currently accounts for over 45% of new
cases of end-stage renal disease carrying with it a dismal
5-year survival rate of 21%, worse than that for all forms of
cancer combined.10–12 The glomerulus is primarily involved
in diabetic nephropathy, with typical histological features
including glomerular basement membrane thickening and
mesangial matrix expansion, with development of protein-
uria reflecting impaired podocyte function.13 At a molecular
level, potential mediators behind the diabetic glomerular
pathology include angiotensin II,14 glucose transporter 1,15
growth hormone,16 transforming growth factor-b,17 platelet-
derived growth factor,18 connective tissue growth factor,19
and advanced glycation end products.20 However, the
underlying pathogenesis is still poorly understood and
remains an area of active investigation.
There are a number of rodent models of types I and II
diabetes mellitus.21 Mutations in the genes that encode either
leptin (Lep) or leptin receptor (Lepr) result in useful mouse
models of obesity and type II diabetes mellitus.22 The
diabetes mutation (db) is due to a point mutation in Lepr,
resulting in a stop codon in the intracellular domain of the
receptor, so that its signaling capacity is curtailed.23
Homozygous Leprdb/Leprdb mice (referred to as db/db)
typically have elevated plasma insulin levels by 2 weeks,
and hyperglycemia and recognizable obesity by 4 weeks of
age. The most severely affected background strain appears to
be C57BLKs, given the ultimate depletion of b cells leading to
insulinopenia and severe hyperglycemia. These mice
also develop hyperfiltration, albuminuria, and mesangial
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expansion,24–26 abnormalities that parallel early human
diabetic nephropathy.21,27 Yet, db/db mice do not have
progressive renal disease, limiting their utility as a true
model of human diabetic nephropathy and prompting a
major search for alternatives.21,28 Overall, given the hetero-
geneity of diabetic nephropathy among humans with diabetes
even with equivalent glycemic control and the relative
resistance of mice to diabetic nephropathy, there are likely
to be genes that confer protection to diabetic nephropathy.29
As one potentially powerful approach to dissect mechan-
isms underlying diabetic nephropathy, microarrays have
recently been used to profile changes in renal gene expression
in glomeruli from human kidney biopsies,26 as well as renal
tissue from mice with type I diabetes mellitus induced with
streptozotocin30,31 and in type II diabetes mellitus occurring
in db/db mice.32,33 These studies have identified some genes
that were differentially regulated in diabetic kidneys com-
pared with their controls. Some limitations of these studies
include the necessarily limited number of glomeruli obtained
from human biopsy specimens, whereas the animal studies
investigated transcriptional changes from whole kidney and
not glomeruli where the majority of disease is concentrated,
at least in early phases of disease. Although there is a gradual
increase in the number of genes included on contemporary
microarrays, available studies are also limited by which genes
are included for study.
In the present study, we followed a large group of db/db and
db/þ mice up to 60 weeks of age. To screen for genes
potentially relevant in the pathophysiology of diabetic nephro-
pathy, high-density oligonucleotide microarrays were used to
profile the glomerular transcriptome from these animals.
Because a significant number of genes observed to be
upregulated in the glomeruli of db/db mice were involved
in vitamin D and Ca2þ metabolism, follow-up studies
concentrated on these genes, their protein products, and
potential downstream effects, with the fundamental hypothesis
that these may confer protection against progressive diabetic
nephropathy.
RESULTS
Differentially expressed genes in diabetic mouse glomeruli
The goal of our study was to identify glomerular genes that
were differentially expressed between db/db and db/þ mice
and correlate these with other features of disease in these
animals using carefully matched conditions. Previous studies
have shown that by 16 weeks, db/db mice develop structural
and functional changes of diabetic nephropathy.26 We
therefore generated littermate db/db and db/þ mice on the
C57BLKs/J background and studied them between 16 and 60
weeks of age. As expected, db/db mice were hyperglycemic,
and developed early albuminuria and mesangial sclerosis
(Table 1); however, these did not worsen as the mice aged up
to 60 weeks (e.g., at no time did urine from a db/db mouse
contain 40.5 mg albumin/mg creatinine). In these animals,
there was also no evidence for renal insufficiency, as
measured by blood urea nitrogen levels.
To screen for genes differentially expressed in glomeruli
from 24-week-old db/db mice relative to db/þ mice, studies
were performed on glomeruli isolated from littermates in
each group. Using a series of relatively stringent filtering
algorithms, 222 of 12 492 candidate genes were significantly
changed, of which 160 genes were upregulated and 62
downregulated in glomeruli from db/db mice compared to
those from db/þ mice (accessible as Supplementary Data at
http://madam.bsd.uchicago.edu). Of the upregulated genes,
23 were included in the gene ontology grouping of Ca2þ
response and regulation (Po0.001); in the further subgroup-
ings of biological processes and molecular functions, each
was involved in Ca2þ ion transport and/or binding. Table 2
shows the listing of these 23 genes, which includes genes
involved in vitamin D metabolism (e.g., 1a-hydroxylase and
vitamin D binding protein (VDBP)), response (e.g., tumor-
associated Ca2þ signal transducers 1 and 2), and Ca2þ
handling (e.g., Calbindin (CaBP) D9K, CaBP D28K, and
Naþ /Ca2þ exchanger, Slc8a1).
To extend upon the validity of these microarray data,
additional experiments were performed using quantitative
reverse transcription-polymerase chain reaction (qRT-PCR)
in glomerular RNA from 20-, 36-, and 52-week-old animals.
As shown in Figure 1, these changes identified by microarray
studies were validated by this alternative method. For all but
calcyclin, there also appeared to be a magnified effect as
animals aged, such that the relative expression in glomeruli
was highest in 52-week-old db/db mice compared to age-
matched db/þ mice.
Vitamin D/Ca2þ physiological studies
Given the altered expression of genes relevant to normal
vitamin D metabolism, additional measurements were made
in db/db and db/þ mice to determine whether these resulted
in physiological changes. Although serum Ca2þ was slightly
elevated in db/db mice, this was not statistically different
from db/þ mice (Table 3). Notably, serum 1,25-dihydroxy-
vitamin D3 levels and urinary Ca
2þ excretion were both
significantly elevated in db/db mice by greater than threefold
compared to age-matched db/þ mice. To evaluate db/db
mice at earlier ages, separate groups of mice (n¼ 7–8) were
studied, which showed that 1,25-dihydroxyvitamin D3 levels
were elevated in db/db mice compared to age-matched db/þ
mice by 38.5% at 6 weeks and 64.4% at 12 weeks (Po0.001
for each group).
Table 1 | Manifestations of diabetes in 24-week-old
db/db mice
db/+ (n=3) db/db (n=3)
Glucose (mg/dl) 140.3724.0 387.3715.7*
Mesangial sclerosis 0.870.2 1.570.1
BUN (mg/dl) 25.272.5 27.570.7
Urine albumin/creatinine (mg/mg) 0.0470.002 0.29708#
Bun, blood glucose and urea nitrogen.
Studied were BUN, urinary albumin excretion normalized to creatinine, and the
extent of mesangial sclerosis (scored from 0 to 4) in histological specimens.
*Po0.05, #Po0.01 versus db/+ mice.
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Although there was a marked increase in VDBP mRNA in
diabetic glomeruli, the baseline mRNA levels were relatively
low. Given this, and consistent with the predominant hepatic
origin of this protein,34,35 there was no difference in serum
VDBP quantities between db/db and db/þ mice (data not
shown).
Identification of protein products in diabetic mouse kidneys
To determine the relevance of the observed transcriptional
changes, kidney expression of 1a-hydroxylase and CaBP D9K
and D28K proteins was determined by immunoblotting. In
both glomeruli and renal cortices, all three proteins were
present in db/þ mice and were increased in db/db mice
(Figure 2). Thus, the alterations in mRNA appear to be
passed along to their translated protein products.
By immunoblotting, the relative expression of 1a-hydro-
xylase in the glomeruli was lower than in the renal cortex,
consistent with the predominant renal tubular localization of
this enzyme in humans and rodents.36–38 To investigate this
further, immunohistochemistry was performed, which
showed the expected expression of 1a-hydroxylase protein
in epithelia of proximal and distal tubules (Figure 3).
However, 1a-hydroxylase was also present in glomerular
parietal and visceral epithelial cells (podocytes, arrows in
Figure 3). These findings are consistent with past studies of
1a-hydroxylase and its promoter in kidneys,37,38 and also
reflect the relatedness of epithelia of the proximal tubule and
the glomerulus.
Studies in cultured podocytes
Given the above findings showing altered mRNA and protein
expression in diabetic mouse glomeruli, coupled with the
Table 2 | Microarray data showing calcium-related genes that were significantly increased in diabetic mouse glomeruli
Accession number Gene symbol Gene title
db/db versus db/+ mRNA
(fold-change) P-value
M55413 Gc Group specific component (VDBP) 8.6670.92 0.001
D26352 Calbl CaBP D28K 6.2470.86 0.002
AB006034 Cyp27b1 Cytochrome P450, 27B1 (la-hydroxylase) 4.3370.84 0.027
J04953 Gsn Gelsolin 3.9570.35 0.002
AB02807I Calb3 CaBP D9K 3.0470.24 0.002
AF004666 Slc8a1 Sodium/calcium exchanger 2.9970.32 0.006
AA839903 Myl7 Myosin, light polypeptide 7 2.7670.32 0.012
X61800 Cebpd C/EBP, delta 2.7470.34 0.015
X66449 S100a6 S100 calcium binding protein A6 (calcyclin) 2.6870.13 0.001
U05809 Tkt Transketolase 2.1870.34 0.049
AI001633 Anxa3 Annexin A3 2.0770.20 0.018
M76124 Tacstd1 Tumor-associated calcium signal transducer 1 2.0370.22 0.032
AI626942 Efhd1 EF hand domain containing 1 1.9970.08 0.001
AV003419 Anxa1 Annexin A1 1.9270.17 0.020
M14044 Anxa2 Annexin A2 1.9070.12 0.006
X99921 S100a13 SI00 calcium binding protein A13 1.8270.10 0.005
AI563854 Tacstd2 Tumor-associated calcium signal transducer 2 1.8170.13 0.013
L27439 Pros1 Protein S (alpha) 1.7770.16 0.043
AI845798 Pla2g12a Phospholipase A2, group XIIA 1.6370.10 0.014
X04017 Sparc SPARC 1.6070.14 0.048
U66166 Sparcl1 SPARC-like 1 1.5970.11 0.023
AI842649 Myl9 Myosin, light polypeptide 9 1.5770.13 0.047
X59382 Pvalb Parvalbumin 1.5270.07 0.008
The relative increase of the listed genes (presented as accession number, gene symbol, and common gene name) in db/db-compared to littermate db/+ glomeruli is
presented in descending order of calculated change, along with the associated P-values.
CaBP, calbindin; C/EBP, CCAAT/enhancer binding protein; SPARC, secreted acidic cysteine-rich glycoprotein; VDBP, vitamins binding protein.
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Figure 1 | Analysis of glomerular gene changes in diabetic mice
over time. RNA was obtained from glomeruli isolated from db/db
and db/þ mice at 20, 36, and 52 weeks of age (n¼ 3 per group)
followed by quantitative RT-PCR for the indicated genes. Data were
normalized to 18S RNA expression from the same samples and
expressed as the ratios of db/db to db/þ samples. Analysis of
variance was used to determine statistical differences, with
generated P-values listed above each gene.
Table 3 | Calcium- and vitamin D-related physiological data
from serum and urine of littermate 24-week-old db/db and
db/+ mice
db/+ (n=61) db/db (n=6)
1,25 dihydroxyvitamin D3 (pg/ml) 103.877.3 314.7745.9*
Calcium (mg/dl) 8.970.4 10.070.7
Phosphate (mg/dl) 7.471.0 8.071.0
Magnesium (mg/dl) 2.570.2 2.870.2
Urine calcium/creatinine (mg/mg) 0.3070.04 1.0670.19*
*Po0.05 versus db/+ mice.
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relevance of the podocyte to diabetic nephropathy, subse-
quent experiments were performed in cultured podocytes.
Compared to low glucose conditions (5 mM), podocytes
incubated in high glucose (25 mM) had increased expression
of 1a-hydroxylase, CaBP 9K, and CaBP 28K (Figure 4)
comparable to what was seen in db/db glomeruli relative to
db/þ mice (shown also in Figure 4 for the purposes of
comparison).
To further confirm the presence of 1a-hydroxylase in
podocytes, RT-PCR was performed to amplify full-length
1a-hydroxylase mRNA. As shown in Figure 5, renal cortex,
glomeruli, and cultured podocytes all had full-length
1a-hydroxylase mRNA, which was confirmed in the latter
by sequencing of the PCR product. The ability of cultured
podocytes to 1a-hydroxylate 25-hydroxyvitamin D3 was
evaluated, as well as whether high glucose conditions (and
induction of 1a-hydroxylase mRNA) would alter this. After
48 h exposure to 50 nM 25-hydroxyitamin D3, supernatant
1,25-dihydroxyvitamin D3 levels were 8.6 and 19.5 pmol/l in
cultured podocytes exposed to 5 and 25 mM glucose,
respectively, illustrating that intrinsic podocyte 1a-hydro-
xylase was functional in these cells and was upregulated
under high glucose conditions.
The relevance of enhanced exposure to 1,25-dihydroxy-
vitamn D3, as we showed occurs in vivo in db/db mice, was
explored by examining podocyte production of the key
Mouse:
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a b c
Figure 3 | Expression of 1a-hydroxylase in the kidneys of diabetic mice. Representative sections from (a) 36-week-old db/þ or (b, c) db/db
mice stained with (a, b) anti-mouse 1a-hydroxylase or (c) normal sheep IgG were shown. Podocytes are depicted by arrows, proximal tubular
epithelium by arrowheads, and distal tubules by asterisks. (a–c) Original magnification 200.
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Figure 2 | Analysis of 1a-hydroxylase, CaBP D28K, and CaBP D9K
proteins in diabetic mice. (a, b) Glomeruli and renal cortices were
obtained from 24-week-old db/db and db/þ mice (n¼ 3 each) and
subjected to Western blotting for the individual proteins. (c) Studies
were carried out in triplicate with representative blots shown in the
figure along with data showing the relative expression of proteins in
db/db mice compared to db/þ mice (C).
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Figure 4 | Effect of high glucose on 1a-hydroxylase, CaBP D28K,
and CaBP D9K mRNA in cultured mouse podocytes. Expression of
the indicated genes normalized to 18S RNA from the same sample is
presented as the ratio from cells cultured in high glucose (HG, 25 mM)
to that from cells cultured in low glucose (LG, 5 mM) (n¼ 3, with each
experiment performed in triplicate). For the purpose of comparison
to data from cultured podocytes, data from 20-week-old db/db and
db/þ glomeruli (as shown in Figure 2) are also presented. *Po0.05
high glucose versus low glucose or db/db versus db/þ .
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Figure 5 | Expression of full-length 1a-hydroxylase mRNA in
diabetic mouse glomeruli and cultured podocytes. RNA samples
from renal cortex and glomeruli from 52-week-old db/db and db/þ
mice and cultured podocytes were subjected to RT-PCR using
primers flanking the coding sequence of 1a-hydroxylase. Controls
lacking RNA were treated identically (lane 1).
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matrix proteins, fibronectin and collagen IV. Cultured
podocytes exposed to 5 mM glucose produced fibronectin
(Figure 6a) and collagen IV proteins (Figure 6b), which were
increased when exposed to high glucose (25 mM) conditions.
Under these conditions, concomitant exposure to 5 nM 1,25-
dihydroxyvitamin D3 led to a reduction in fibronectin and
collagen IV production.
Finally, given the clear importance of vitamin D receptor
(VDR) to the effects of 1,25-dihydroxyvitamin D3, its cellular
expression was also assessed. Cultured podocytes in low
glucose medium expressed VDR proteins of 48- and 53-kDa
(Figure 7), which by analogy to human VDR are likely to
be VDRA and VDRB1, respectively.39 The quantity of the
48-kDa VDR was increased modestly (but consistently) in
high glucose conditions, whereas both forms were increased
further upon exposure to 1,25-dihydroxyvitamin D3.
DISCUSSION
In this study, the transcriptional basis of diabetic nephro-
pathy in the form exhibited in C5BLKs/J db/db mice was
evaluated. Here we concentrated on glomeruli, where the
major changes occur at least early on in the disease process.
As is well known to occur, features of diabetic nephropathy
were apparent in the cohort studied here, including
albuminuria and mesangial matrix accumulation.22,24 Yet,
there was no evidence of progressive renal disease up to 60
weeks of age by functional or pathological criteria, which is a
recognized limitation of this model as truly reflective of
human diabetic nephropathy.21,28 Given that glomeruli
comprise a small fraction of total renal cortical transcripts,
it is not possible to make direct comparisons to previous
studies in db/db mice in which whole renal tissue was
studied.32,33 It is also notable that the studies by Susztak
et al.32 utilized proprietary cDNA arrays, whereas those by
Mishra et al.33 used Affymetrix oligonucleotide arrays, as we
did. We therefore compared our data with those from the
latter study, and identified 64 genes in common between our
list of 222 genes and their 1016 genes, respectively (see
Supplementary Data). Of the 23 genes in Table 2, five were in
common between the two studies, which were 1a-hydro-
xylase, CaBP D9K, CaBP D28K, myosin light polypeptide
regulatory 7, and transketolase. All five are relatively highly
expressed in db/db glomeruli, and the former three were also
documented in the whole kidney. Overall, the concordance of
28.8% (64/222) between the two studies is quite good.
Besides the obvious issue of the whole kidney or isolated
glomeruli being studied, there were also different approaches
used in data analyses, with ours using the more contempor-
ary robust multichip analysis approach, followed by statistical
and threshold filtering.
In a short-term study in streptozotocin-induced type I
diabetes in rats,40 there was marked hypercalciuria, yet,
serum 1,25-dihydroxyvitamin D3 levels were decreased rather
than increased as in our study; it is conceivable, these
phenomena are related more to the toxicities of streptozo-
tocin than diabetes.41 The effects of leptin on 1a-hydroxylase
and calcium metabolism have been shown in a recent study
in ob/ob mice,42 which represent a similar obese type II
diabetes mellitus model as db/db mice. These mice had
increased levels of 1a-hydroxylase and urinary calcium, which
could be normalized in the short-term (48 h) by providing
exogenous recombinant leptin.42 In those studies, the acute
effect of leptin on blood glucose was not reported, whereas in
our studies we were unable to dissect the roles of impaired
leptin signaling from those of hyperglycemia. Our ongoing
experiments of transplanting normal kidneys (with normal
leptin receptors) into hyperleptinemic and hyperglycemic
db/db recipients will help address the relative roles of leptin
and glucose on these findings.
It is notable that while 1a-hydroxylase is traditionally
considered a proximal tubular protein,36 contemporary
studies have shown a much more widespread distribution
in the kidney.43 Furthermore, 1a-hydroxylase is also known
to be expressed outside of the kidney, such as in
macrophages,44 bone cells,45 and keratinocytes.46 In the
kidney, distal convoluted tubules and epithelia of the
glomerulus have evidence for 1a-hydroxylase expression.38
The proximal tubular 1a-hydroxylase clearly has a major
endocrine role. In this system, which has now been well
worked out, 25-hydroxyvitamin D3 bound to VDBP is
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Figure 6 | Effects of high glucose and physiological 1,25-dihydroxy-
vitamin D3 concentrations on (a) fibronectin and (b) collagen IV
expression in cultured podocytes. Mouse podocytes were
cultured low glucose (LG, 5 mM) or high glucose (HG, 25 mM)
in the presence or absence of 5 nM 1,25-dihydroxyvitamin D3.
Representative Western blots for fibronectin and collagen IV with
data derived by densitometry are shown (n¼ 4, with each
experiment performed in triplicate). *Po0.02 versus low glucose
and high glucose plus 1,25-dihydroxyvitamin D3.
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Figure 7 | Effects of high glucose and physiological 1,25-dihydroxy-
vitamin D3 concentrations on VDR expression in cultured
podocytes. Mouse podocytes were cultured in low glucose (5 mM)
or high glucose (25 mM) in the presence or absence of 5 nM
1,25-dihydroxyvitamin D3. A Western blot representative of
eight experiments are shown.
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filtered at the glomerulus and taken up by the proximal
tubule in a megalin-dependent manner.43,47 In the proximal
tubular mitochondria, 25-hydroxyvitamin D3 is 1a-hydroxy-
lated and then active 1,25-dihydroxyvitamin D3 is exported
to the capillaries at the basal surface to join the systemic
circulation. Enhanced renal 1a-hydroxylation of 25-hydroxy-
vitamin D3 has been noted in db/db mice,
41 which is
consistent with our findings of increased renal 1a-hydro-
xylase protein mass and its 1,25-dihydroxyvitamin D3
product in plasma. In other cells, the production of 1,25-
dihydroxyvitamin D3 is believed to serve more of a paracrine
and/or autocrine role.3–5,48 This would appear to be the case
also for podocytes, given the barrier to their contributing
1,25-dihydroxyvitamin D3 to the plasma pool. It is notable
that podocytes in the rat bear megalin, whereas those of
humans and mice do not.49
The VDRs are also appreciated to have a widespread
distribution with a myriad of potential effects.3,4 Unlike many
other endocrine receptors, VDRs are the product of a single
gene, with little transcriptional and translational modifica-
tion.4 In humans, there are three VDR isoforms that have
been recently described – the classic 48-kDa VDRA and two B
isoforms, VDRB1 and VDRB2.39 Interestingly, here we found
in cultured mouse podocytes what we presume to be VDRA
and VDRB1, the former of which was upregulated in high
glucose conditions. VDRB1 was further increased in these
cells exposed to 1,25-dihydroxyvitamin D3 which could
represent an effect on VDRB1 transcripts and/or existing
VDRB1 protein.50,51 The actions of these VDRs when bound
to RXR and 1,25-dihydroxyvitamin D3 vary considerably
depending on the cell system studied.52 These transcriptional
effects certainly have relevance to diabetes mellitus, such as in
cells of the immune system in autoimmune type I diabetes
mellitus and also in pancreatic b-cells to downregulate major
histocompatibility complex molecule expression and increase
insulin release.8,9,53 The converse that insulin, or its resistance
in diabetes, has direct actions on the vitamin D system is
conceivable, although apparently not a prominent effect.41
Podocytes are key glomerular cells by virtue of their serving
as the final barrier to protein passage across the glomerular
capillary wall whereas at the same time permitting the
abundant glomerular ultrafiltrate to pass; as well, they
contribute significantly to the production and maintenance
of the glomerular basement membrane matrix.54 Thus,
podocyte pathology can have a major contribution to diabetic
nephropathy, such as through a reduction in podocyte density
along the glomerular basement membrane, abnormalities in
the specialized slit diaphragm, and by contributing to abnormal
glomerular basement membrane structure.55–57 There is a
growing body of data suggesting that 1,25-dihydroxyvitamin
D3 is protective in glomerular disease, particularly in condi-
tions associated with excess matrix production.58,59 A recent
report has been illustrative in showing that 1,25-dihydrox-
yvitamin D3 can inhibit renal interstitial myofibroblasts, an
effect attributed to stimulation of hepatocyte growth factor.60
In the rat remant kidney model, 1,25-dihydroxyvitamin D3
protected against podocyte injury associated with their loss and
hypertrophy, which was felt to explain the protection against
glomerulosclerosis in this model.61 A protective role of 1,25-
dihydroxyvitamin D3 in diabetic nephropathy could also be
attributed to its negative regulation of the renin–angiotension
system,62 in keeping with the known renal benefits of blocking
angiotensin II receptors in both humans and rodents with
diabetes.63,64 In the present study, our supposition that 1,25-
dihydroxyvitamin D3 was protective against diabetic nephro-
pathy is admittedly indirect, in that elevated 1,25-dihydrox-
yvitamin D3 levels were associated with the lack of progression
of diabetic nephropathy in db/db mice. Yet, in studies with
cultured podocytes, we showed that 1,25-dihydroxyvitamin D3
inhibited the glucose-stimulated production of fibronectin and
collagen IV, which may be one link to explain this
phenomenon. In our preliminary studies (Sun L, Liu J, Kong
J, Han M, Zhang Z, Li YC. Renal protective role of vitamin D in
the development of diabetic nephropathy. American Society of
Nephrology Renal Week 2005, Abstract TH-FC014), VDR-
deficient mice with stretptozotocin-induced diabetes had much
more severe disease than wild-type controls, whereas treatment
with the vitamin D analogue, RO-27-5646, further limited
disease in the latter animals, data in direct support of our
contention here that an activated vitamin D system can be
protective in diabetic nephropathy.
Besides 1a-hydroxylase, 1,25-dihydroxyvitamin D3, and
VDR, other products of potential relevance to diabetic
nephropathy that were observed to be increased in db/db
glomeruli included the calbindins, CaBP-D9K, and -D28K.
These calbindins are well-known vitamin D targets;65 thus,
their upregulation may well be the result of increased 1a-
hydroxylase activity in db/db mice. Both bind intracellular
Ca2þ with high affinity and play key roles in vitamin
D-mediated transcellular Ca2þ transport across intestinal and
renal tubular epithelia.66,67 CaBP-D28K has also been shown
to suppress cell apoptosis,65 which is certainly relevant in the
context of diabetic nephropathy as discussed above. The
expression of high levels of these CaBP in glomeruli raises new
questions regarding their potential function in this site.
In summary, we have shown here that in db/db mice,
hyperglycemia and/or impaired signaling through the leptin
receptor leads to upregulated 1a-hydroxylase in the kidney
with resultant increased circulating 1,25-dihydroxyvitamin
D3 levels with its attendant hormonal effects, such as
hypercalcuria. As the podocytes bear VDR, its engagement
by 1,25-dihydroxyvitamin D3 from the systemic circulation,
as well as that which is locally produced, has the potential to
be a protective response to the metabolic derangements in
diabetes mellitus. Our data support that the transcriptional
effects of VDR may prevent mice from developing features
evident in human diabetic nephropathy.
MATERIALS AND METHODS
Animal studies
Because of the greater severity of renal disease in db/db mice on the
C57BLKs/J background,21,25 this was the background strain used for
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these studies. Breeding pairs heterozygous for both Leprdb and the
misty trait (m) (original designation, C57BL/KsJ-mþ /þ Leprdb;
current designation, BKS.Cg-mþ /þ Leprdb/J; stock number
000642) were purchased from Jackson Laboratories (Bar Harbor,
ME, USA). Db/þ mice were interbred to generate db/þ and db/db
mice, the latter identified by early-onset obesity and hyperglycemia,
whereas the former was distinguished from mice homozygous for
wild-type Lepr by gray coat color conferred by the misty trait (mþ /
mþ ). After weaning, all db/þ and db/db mice had free access to
water and Teklad Global 18% Protein Rodent Diet 2918, containing
1.01% calcium and 38.4 ng/g (1.54 IU/g) vitamin D3. Beginning at
20 weeks of age and extending in 4-week intervals until a final group
reached 60 weeks of age, three littermate animals per group had
urine and blood collected followed by euthanasia for renal tissue
harvest. These studies were approved by The University of Chicago
Institutional Animal Care and Use Committee.
Measurements from serum and urine
For 24-h urine collections, mice were placed in individual metabolic
cages. Blood was collected by cardiac puncture. Urea nitrogen,
creatinine, calcium, phosphate, and magnesium in urine and serum
were detected with a Beckman Autoanalyzer (Beckman Coulter,
Fullerton, CA, USA). Urinary albumin concentration was measured
by a mouse albumin enzyme-linked immunosorbent assay kit
(Bethyl Laboratories, Montgomery, TX, USA), and normalized to
urinary creatinine. Blood glucose was measured with a glucose
monitor (OneTouch SureStep, LifeScan, Inc., Milpitas, CA, USA).
Measurements of 1,25-dihydroxyvitamin D3 were made by radio-
immunoassay (ImmunoDiagnostic System, Boldon, UK).
Tissue processing
Glomeruli from one kidney were isolated by injection of iron oxide
particles into the renal artery followed by magnetic purification;68
glomeruli of high purity (498%) were confirmed by phase contrast
microscopy and harvested for subsequent analyses. Renal cortex
from the contralateral kidney was processed by standard techniques
for protein and mRNA isolation and histological studies.
Microarray analyses of db/db and db/þ glomerular mRNA
Target preparation for microarray hybridizations was based on
protocols supplied by Affymetrix (Santa Clara, CA, USA) with
minor modifications. Briefly, total RNA from glomeruli isolated
from db/db and db/þ kidneys (n¼ 3 for each group) was extracted
using TRIZOL (Invitrogen, Carlsbad, CA, USA). The quality of all
RNA samples was assured by evaluation on an Agilent Technologies
2100 Bioanalyzer (Palo Alto, CA, USA). Ten micrograms of total
RNA were used to synthesize double-stranded cDNA using the
SuperScript Choice System (Invitrogen). First-strand cDNA synth-
esis was primed with a T7-(dT24) oligonucleotide. Biotin-labeled anti-
sense cRNA was synthesized from 3 mg cDNA using a BioArray High
Yield RNA Transcript Labeling Kit (Enzo Diagnostics, Farmingdale,
NY, USA). After precipitation with 4.0 M lithium chloride, 20 mg
cRNA was fragmented in 40 mM tris-acetate, pH 8.1, 100 mM KOAc,
30 mM MgOAc buffer for 35 min at 941C and then hybridized with
Affymetrix Mu74v2 arrays for 16 h at 60 r.p.m. and 451C. The arrays
were washed and stained with streptavidin phycoerythrin and then
scanned with a GeneArray Scanner (Affymetrix).
Microarray image files were obtained through Affymetrix
GeneChip software (MAS 5.0). Array quality was examined
according to Affymetrix protocols and then by dChip (dChip.org)
to determine the percentage of outliers on each array. Subsequent
robust multichip analysis was performed. Robust multichip analysis
is an R-based technique that analyzes directly from the Affymetrix
microarray .cel image file and is comprised of three steps:
background adjustment, quantile normalization, and summariza-
tion. In the Windows operating system, the robust multichip
analysis express function was used to process the data. The outputs
were log2 transformed expression index data for each probe set.
Filtering of genes was performed in the following way: first, the
mean expression index data of genes in each group was calculated;
differences of the mean values of each gene across the experimental
and control group were calculated next. A two-tailed t-test was
subsequently performed to check for potential differences between
experimental and control groups. For the threshold values, as the
data were log2 transformed, a difference of 1.0 would equal a
twofold change. Here we used a difference of 0.6 which equals a 1.5-
fold change as a threshold. For the t-test, we used 0.05 as threshold.
Genes meeting both the difference and t-test criteria were selected.
Gene ontology relationships and their significance were determined
using the Gene Onotology function in GeneSpring software (v. 6.0,
Agilent Technologies).
Studies with cultured murine podocytes
Experiments were performed with a murine glomerular visceral
epithelial cell (podocyte) line kindly provided by Dr Peter Mundel
(Mount Sinai Medical College, New York, NY, USA). Podocytes were
first grown to B80% confluence in collagen-coated flasks under
permissive conditions for the SV40T antigen which is at 331C in
Roswell Park Memorial Institute-1640 medium with 10% fetal
bovine serum and 50 U/ml g-interferon. The cells were then
subcultured in the same medium but at 371C and without
g-interferon (nonpermissive conditions) and grown to B50%
confluence. The medium was then changed to Dulbecco’s modified
Eagle’s medium (1.8 mM CaCl2), 0.5% fetal bovine serum without
g-interferon to arrest and synchronize cell growth. Cells were then
studied in g-interferon-free Dulbecco’s modified Eagle’s medium
containing 5% fetal bovine serum and a final glucose concentration
of 5 or 25 mM. After 96 h, the medium was removed and cellular
RNA was isolated for subsequent analyses. In additional experi-
ments, vitamin D was added either as 50 nM 25-hydroxyvitamin D3
or 5 nM 1,25-dihydroxyvitamin D3 (Sigma-Aldrich Co., St Louis,
MO, USA) which was replenished 24 h later. After 48 h, the culture
medium was removed and cellular proteins isolated for immuno-
blotting. The measurement of 1,25-dihydroxyvitamin D3 in the
supernatant was measured by radioimmunoassay as described for
serum samples; as a control (blank) for these experiments, medium
containing 25-hydroxyvitamin D3 was incubated in wells lacking
cells in parallel.
Reverse transcription-polymerase chain reaction
Total RNA was isolated from cultured podocytes, glomeruli, and
renal cortices using TRIZOL. The RNA was converted to cDNA
using SuperScript First-Strand Synthesis System (Invitrogen). To
document the presence of full-length mRNA for 25-hydroxyvitamin
D3 1a-hydroxylase (cytochrome P450, 27b1), 50-ATATGGTCTGG
CAGCTTTGG-30 and 50-CTGCTTCCTGGAGTTTGCTC-30, were
used to amplify its gene fragment. PCR products were verified by
DNA sequencing.
For quantitative real-time RT-PCR reactions, gene-specific
primers for selected genes (Table 4) were used with the SYBR
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Green kit (Qiagen, Valencia, CA, USA) on an ABI Prism 7700
Sequence Detection System (Applied Biosystems, Foster City, CA,
USA). Murine 18S RNA was used for normalization. In preliminary
studies, the specificity of each primer pair was validated by DNA
sequencing of each PCR product.
Histological studies
Unless stated otherwise, all procedures were performed at room
temperature. Periodic acid Schiff-stained kidney sections were
evaluated by a renal pathologist (MH) for the extent of mesangial
sclerosis and hyperceullarity using a numeric scale of 0–4.69 Sections
of 4 mm cut from paraffin-embedded db/db and db/þ kidneys were
fixed with cold methyl Carnoys. After deparaffinization and
hydration of tissue sections, slides were incubated with 0.3%
hydrogen peroxide in phosphate-buffered saline (PBS) to block
endogenous peroxidase activity. After washing with three changes of
PBS, slides were heated for 11 min in a microwave in 10 mM sodium
citrate, pH 6.0. The slides were blocked with 10% donkey serum in
PBS followed by an avidin/biotin block (SP-2001, Vector Labora-
tories, Burlingame, CA, USA). After washing with PBS, the slides
were incubated overnight at 4 1C with sheep anti-mouse 1a-
hydroxylase (The Binding Site, San Diego, CA, USA; 1:400 in 10%
donkey serum) or nonimmune sheep serum as control. With
intervening PBS washing steps, the slides were incubated sequen-
tially with biotinylated anti-sheep IgG (Sigma-Aldrich; 1:100 in 10%
donkey serum), avidin–biotin enzyme reagent (1:50 in PBS) and
diaminobenzidine peroxidase substrate solution (Vector Labora-
tories Vectastain ABC kit). The slides were washed in water and
counterstained with Mayer’s hematoxylin. In all cases, the observer
was masked to the origin of the slides.
Immunoblotting
Renal cortex and isolated glomeruli from db/db and db/þ mice, and
cultured podocytes were homogenized in radioimmunoprecipita-
tion assay buffer (PBS including 1% Nonidet P-40, 0.5% sodium
deoxycholate, 0.1% sodium dodecyl sulfate and a protease inhibitor
cocktail (Roche, Indianapolis, IN, USA)). The supernatant was
collected after centrifugation at 13 000 r.p.m. for 30 min at 41C.
Protein concentrations were determined with bicinchoninic acid
(Pierce, Rockford, IL, USA) using bovine serum albumin as a
standard. Equal amounts of proteins or volumes of sera were
subjected to sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis and electrophoretically transferred to a polyvinylidene
diflouride membrane (Millipore, Bedford, MA, USA). Membranes
were blocked with 5% nonfat milk for 2 h at room temperature and
incubated with the following dilutions of primary antibodies: 1:500
sheep anti-mouse 1a-hydroxylase and 1:5000 rabbit anti-mouse
CaBP D9K (Swant, Bellinzona, CH); 1:5000 rabbit anti-mouse CaBP
D28K (Chemicon International, Inc, Temecula, CA, USA); 1:2000
rabbit anti-mouse VDBP (Biodesign International, Saco, ME, USA);
1:1000 rabbit anti-mouse VDR and 1:500 anti-mouse collagen IV
(Santa Cruz Biotechnology, Santa Cruz, CA, USA); and, 1:1000
rabbit anti-mouse fibronectin and b-actin (Sigma-Aldrich). Mem-
branes were then incubated with peroxidase-conjugated anti-sheep
or rabbit IgG (1:3000 and 1:1500, respectively, Sigma-Aldrich),
which were detected with the SuperSignal West Dura Chemilumine-
scent Kit (Pierce).
Statistical analyses
The ratio of a given mRNA to 18S RNA or protein to b-actin from
the same sample measured at the same time was calculated. Owing
to their nonparametric nature, data were logarithmically (loge)
transformed. For comparisons over time, Bonferroni-adjusted
P-values from an analysis of variance model that adjusted for age
groups (20, 36, and 52 weeks) were derived using Stata software
(v. 8, Stata Corp., College Station, TX, USA). Comparisons between
two groups were made by t-testing.
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